Previous close | 26.34 |
Open | 25.65 |
Bid | 25.51 x 3100 |
Ask | 25.51 x 800 |
Day's range | 25.40 - 25.83 |
52-week range | 21.53 - 33.09 |
Volume | |
Avg. volume | 940,001 |
Market cap | 11.126B |
Beta (5Y monthly) | 0.51 |
PE ratio (TTM) | 42.42 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.75 (2.85%) |
Ex-dividend date | 01 Apr 2024 |
1y target est | N/A |
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been named the Preferred Sports Medicine Technology Partner of UFC – the world’s premier mixed martial arts organization and one of the foremost global brands in all of sports. Under the terms of the multi-year partnership, Smith+Nephew will activate its brand through UFC’s immense global presence to promote the repair, regeneration and recovery of Sports Medicine injuries through advanced technologies
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced they have entered into a Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR). This marks the first time that the USAISR has entered into a master agreement of this nature with an industry-leading medical technology company. The Master CRADA represents an enterprise-wide opportunity for Smith+Nephew across all business units - Advanced Wound
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces full commercial availability of its AETOS Shoulder System in the US, along with 510(k) clearance for its use with ATLASPLAN◊ 3D Planning Software and Patient Specific Instrumentation for total shoulder arthroplasty. Total shoulder arthroplasty is one of the fastest growing segments in Orthopaedics with an estimated 250,000 procedures in the US by 2025.1 Developed to restore patients’ range-of-motion2-5 and he